Encyclopedia entry
GHRP-6 (Growth Hormone Releasing Peptide-6)
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-26
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · GHRP-6
GHRP-6 is a synthetic hexapeptide ghrelin receptor agonist, developed in the late 1980s and one of the earliest growth hormone secretagogues to be characterised in humans. It triggers pulsatile release of endogenous growth hormone and produces pronounced appetite stimulation via the ghrelin pathway, which is its key distinguishing feature within the GHRP family. Development as a licensed pharmaceutical was discontinued and it holds no marketing authorisation in any major jurisdiction. No phase II or phase III randomised trials of efficacy for body composition, athletic performance, or anti-ageing have been published. PeptideClear is gathering UK retailer data for GHRP-6; commercial coverage is not yet live.
Mechanism of action
How GHRP-6 works
GHRP-6 binds the growth hormone secretagogue receptor type 1a (GHSR-1a, the ghrelin receptor) on the anterior pituitary and at the hypothalamic arcuate nucleus. Receptor activation triggers pulsatile release of stored endogenous growth hormone from somatotroph cells. GHRP-6 is notable within the GHRP family for marked stimulation of appetite via the ghrelin pathway, which has made it a tool compound in appetite-regulation research alongside its growth hormone secretagogue activity. Older human pharmacokinetic work documented a short plasma half-life on the order of 15 to 30 minutes, consistent with the pulsatile release profile.
Source: PubMed search: GHRP-6 pharmacokinetics (late 1980s and 1990s human characterisation literature)
What the literature shows
The GHRP-6 literature splits into three strands. The first is the older pharmacokinetic characterisation in healthy adult volunteers and in growth-hormone-deficient populations, mostly from the late 1980s and 1990s, which established the ghrelin receptor binding profile and the GH-releasing activity. The second strand is the appetite-regulation literature, where GHRP-6 has been used as a tool compound to interrogate the ghrelin-driven appetite pathway. The third is broader ghrelin receptor and growth-hormone secretagogue class research. Recent efficacy trials for any specific therapeutic indication are absent.
- · Human pharmacokinetic studies in healthy adult volunteers establishing absorption, half-life, and dose-response GH release profiles (late 1980s and 1990s).
- · Documentation of pronounced appetite stimulation via the ghrelin pathway, distinguishing GHRP-6 from the more GH-selective GHRP-2.
- · GH stimulation testing in paediatric growth-hormone-deficient populations as a diagnostic challenge in older clinical workups.
- · Use as a tool compound in ghrelin receptor and appetite regulation research from the 1990s onwards.
- · Animal model work on appetite, body weight, and growth hormone axis biology.
- · No published phase II or phase III randomised controlled trials of efficacy for body composition, athletic performance, or anti-ageing indications in healthy adults.
- · Listed on the WADA prohibited list for tested athletes, alongside other growth hormone secretagogues.
Related compounds: GHRP-2 (see GHRP-2 encyclopedia entry) is the sibling compound in the GHRP family with greater GH release and less appetite effect. Hexarelin (see Hexarelin encyclopedia entry) is the third GHRP-family compound, distinctive for additional CD36 cardiovascular receptor binding. Ipamorelin is the newer, more selective GHRP with the least cortisol and prolactin elevation.
UK regulatory status
GHRP-6 sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It has zero UK marketing authorisations as a medicine. UK retailers can sell it lawfully only by labelling it for "research use only, not for human or animal consumption" and by avoiding any therapeutic claim. It is also on the WADA prohibited list, which is relevant to any tested athlete.
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No UK marketing authorisation as a medicine.
- · No EMA or FDA marketing authorisation in the EU or US.
- · Sold legally as a research chemical when marketed without health claims.
- · Listed on the WADA prohibited list. Use by a UKAD-tested athlete results in a sanctionable doping finding.
- · Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Risks and unknowns
What the literature does not yet show about GHRP-6
Known concerns
- Older human pharmacokinetic studies do not constitute efficacy or long-term safety evidence for any consumer indication.
- Pronounced appetite stimulation via the ghrelin pathway is a documented and distinguishing secondary effect, with unclear long-term metabolic implications.
- Reported transient elevations in cortisol and prolactin relative to newer, more selective GHRPs such as Ipamorelin.
- WADA prohibited status. Athletes subject to UKAD or international federation testing risk a doping sanction.
- Purity of UK research-peptide supply varies. CoA gating and HPLC analysis differ between retailers.
Open questions in the literature
- Long-term effects of repeated GH axis stimulation in healthy adults are not characterised in modern ICH-GCP trials.
- Whether the GH release translates into any measurable change in lean mass, fat mass, or athletic performance in healthy adults has not been formally established.
- Whether the pronounced appetite-stimulation effect carries metabolic consequences (weight gain, insulin sensitivity changes) on a longer timescale has not been formally studied.
- Interactions with other components of the GH/IGF-1 axis (CJC-1295, Sermorelin, exogenous growth hormone) are not characterised in controlled human trials.
Regulatory note
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Listed on the WADA prohibited list. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Where to learn more
- · PubMed search: GHRP-6 returns several hundred papers covering pharmacokinetics, ghrelin receptor pharmacology, and appetite research.
- · PubMed: GHRP-6 pharmacokinetics for the late 1980s and 1990s human characterisation literature.
- · PubMed: GHRP-6 appetite for the ghrelin-driven appetite-regulation research strand.
- · PubMed: ghrelin receptor agonist for broader GHSR-1a pathway context.
- · Related compounds: GHRP-2, Hexarelin, Ipamorelin.
- · UK retailer purity comparison: research peptides UK retailers.
- · WADA prohibited list: wada-ama.org prohibited list.
Frequently asked questions
Is GHRP-6 legal in the UK?
What does the human evidence show for GHRP-6?
What is the regulatory status of GHRP-6 in the UK?
How does GHRP-6 differ from GHRP-2 and Hexarelin?
Where can I learn more about GHRP-6?
UK retailer coverage
PeptideClear is gathering UK retailer data for GHRP-6. Commercial price comparison and retailer table not yet live for this compound. In the meantime, the UK research peptide retailer directory covers the broader supply landscape.
UK research peptide retailersClinical evidence record
Read the clinical evidence record for GHRP-6
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy GHRP-6 in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.